Screener
Halozyme Therapeutics HALO Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $481M+47.7% | $376.71M+42.2% | $451.77M+51.6% | $354.26M+22.1% | $325.72M+40.8% | ||
| $79.17M+70.8% | $79.24M+63.7% | $78.77M+87.3% | $55.24M+11.8% | $46.36M+17.0% | ||
| $401.83M+43.8% | $297.47M+37.4% | $373M+45.7% | $299.02M+24.3% | $279.36M+45.7% | ||
| 83.5%-2.2pp | 79%-2.8pp | 82.6%-3.3pp | 84.4%+1.4pp | 85.8%+2.9pp | ||
| $27.66M+57.7% | $25.56M+72.7% | $31.9M+56.0% | $17.25M-6.5% | $17.54M-16.6% | ||
| $57M+37.0% | $57.88M+36.6% | $77.03M+82.3% | $46.09M+11.8% | $41.61M+16.5% | ||
| $193.35M+56.8% | $192.19M+55.8% | $544.66M+345% | $136.34M+7.5% | $123.28M+8.0% | ||
| $287.65M+42.1% | $184.52M+30.4% | —— | $217.92M+33.5% | $202.44M+72.7% | ||
| 59.8%-2.3pp | 49%-4.5pp | —— | 61.5%+5.3pp | 62.2%+11.5pp | ||
| $5.59M+27.2% | $5.51M+21.7% | $4.91M+8.2% | $4.3M-5.0% | $4.39M-2.9% | ||
| $2.84M-58.8% | $1.32M-80.7% | $2.43M-66.5% | $5.33M-17.6% | $6.89M+36.9% | ||
| $284.9M+39.0% | $180.33M+25.4% | —— | $218.96M+32.6% | $204.94M+74.1% | ||
| $54.99M+38.2% | $30.28M+17.7% | $40.74M-1.1% | $43.73M+55.4% | $39.78M+62.4% | ||
| $229.91M+39.2% | $150.05M+27.1% | —— | $175.23M+27.9% | $165.16M+77.1% | ||
| 47.8%-2.9pp | 39.8%-4.8pp | —— | 49.5%+2.2pp | 50.7%+10.4pp | ||
| $1.90+42.9% | $1.22+31.2% | —— | $1.43+36.2% | $1.33+84.7% | ||
| $292.15M+42.4% | $188.74M+30.9% | —— | $220.62M+33.1% | $205.14M+71.2% | ||
| 60.7%-2.2pp | 50.1%-4.4pp | —— | 62.3%+5.1pp | 63%+11.2pp | ||
| $287.65M+42.1% | $184.52M+30.4% | —— | $217.92M+33.5% | $202.44M+72.7% |
FAQ
- What is Halozyme Therapeutics's revenue?
- Halozyme Therapeutics (HALO) generated $1.7B in revenue over the trailing twelve months, up 41.1% year over year.
- Is Halozyme Therapeutics profitable?
- Halozyme Therapeutics reported $720.3M in net income over the trailing twelve months, a 47.9% net margin.
- What are Halozyme Therapeutics's profit margins?
- Gross margin is 82.4% and operating margin is 59.3%, with a 47.9% net margin.
- What is Halozyme Therapeutics's earnings per share?
- Halozyme Therapeutics's diluted EPS over the trailing twelve months is $5.88.
- Where does Halozyme Therapeutics's income statement data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
